TNFAIP3 interacting protein 2Genealiases: ABIN2 · FLIP1 · KLIP
Q-omics provides the consensus-scored TNIP2 profile across patient tissues and cancer cell-line models. TNIP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNIP2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TNIP2 protein abundance shows 22,958 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where TNIP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNIP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNIP2 survival associations across molecular data types. TNIP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNIP2 RNA expression–survival associations across cancer types. High TNIP2 expression shows unfavorable associations in KIRC, UVM, KICH, ACC and LUAD, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TNIP2 RNA expression.
This table summarizes TNIP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNIP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNIP2 shows higher tumor expression in HNSC, LIHC, KIRC, THCA, STAD and CHOL. The HNSC box plot shows higher TNIP2 RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with TNIP2 in patient tissues and cancer cell lines. In patient samples, TNIP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNIP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
